Objectives: Carbon monoxide poisoning affects 50,000 per year in the United States alone. Mortality is approximately 3%, and up to 40% of survivors suffer from permanent neurocognitive and affective deficits. Hyperbaric oxygen therapy has shown benefit on reducing the long-term neurologic sequelae of carbon monoxide poisoning but has not demonstrated improved survival. The objective of this study is to assess the efficacy of hyperbaric oxygen for acute and long-term mortality in carbon monoxide poisoning using a large clinical databank. Design: Retrospective analysis. Setting: University of Pittsburgh Medical Center healthcare system (Pittsburgh, PA). Patients: One-thousand ninety-nine unique encounters of adult patients with carbon monoxide poisoning.
C arbon monoxide (CO) poisoning affects approximately 50,000 patients yearly in the United States alone. There are approximately 1,000-2,000 deaths per year in nonfire-related poisonings (1, 2) . Management consists of normobaric oxygen, hyperbaric oxygen therapy (HBo 2 ), and supportive care. Among survivors of CO poisoning, 15-40% suffer from permanent neurocognitive and affective deficits (3, 4) . CO poisoning can induce cardiac dysfunction, ranging from myocardial infarction to arrhythmias, complications that are associated with increased mortality (5, 6) . There is evidence that survivors of CO poisoning have increased long-term mortality (5) (6) (7) .
Supplemental oxygen therapy and HBo 2 act by significantly reducing the carboxyhemoglobin half-life in blood (1, 2, (8) (9) (10) . Only about 1,500 patients will receive HBo 2 according to a large clinical database of hyperbaric medicine centers (11) . Clinical trials suggest that HBo 2 reduces the longer term neurocognitive morbidity after CO poisoning (1, 8, 12) . Other studies have not replicated this benefit (13) , leading to controversy over the actual efficacy and utility of HBo 2 (1, 14, 15) . There are risks of HBo 2 in the critically ill population including middle ear barotrauma, pulmonary barotrauma, and oxygen toxicity (16) .
There are logistical difficulties in caring for critically ill patients in a hyperbaric chamber; only certain centers have the appropriately trained personnel and specialized equipment necessary for HBo 2 in the critically ill population (16) . Due to the low mortality and the relatively low prevalence of the disease, no randomized clinical trial has been designed to show a mortality benefit of HBo 2 (2, 13) . More research is needed into both HBo 2 utility and other possible forms of therapy (1, 14, 15, 17) .
In this study, we have used the medical record database of a large regional health system to define the clinical characteristics of patients who receive HBo 2 and to characterize the acute and long-term mortality of patients who experience CO poisoning. We sought to identify if HBo 2 was associated with improved short-term and long-term outcomes.
METHODS

Study Design
This was a retrospective cohort study of patients with CO poisoning seen in an emergency department or directly admitted within the University of Pittsburgh Medical Center, a large regional healthcare system in Western Pennsylvania. Patients age greater than or equal to 18 years old with a CO poisoning diagnosis at hospital discharge were identified using International Classification of Diseases, 9th revision, Clinical Modification (ICD-9-CM), codes. Patients included in this study had the following ICD-9-CM codes: 986, E868.3, E868.8, E868.9, E982.1, E982.1, E868.2, or E982.0. Patients were identified through an electronic medical record data repository that contains full-text medical records and integrates information from central transcription, laboratory, pharmacy, finance, administrative, and other departmental databases (18) . With the approval of the University's institutional review board and to maintain patient confidentiality, data were deidentified using De-ID software (University of Pittsburgh, Pittsburgh, PA) through the use of an honest broker system, and the data were obtained with a waiver of informed consent (19) . For patients with multiple admissions during the study period, the first admission meeting all inclusion criteria was considered the index hospitalization. We identified 1,306 encounters in 15 hospitals over the study period. After combining duplicate encounters for the same visit and excluding those less than 18 or unknown age, there were 1,099 unique patient encounters with CO poisoning analyzed (Fig. 1) .
Data Collection
Baseline demographics, laboratory values, hospital charge transactions, medical record discharge abstract data, and discharge disposition were obtained from the medical record data repository. Two academic internal medicine physicians reviewed the deidentified reports for each visit to record the mechanism of poisoning, symptoms, cardiac involvement, presence of a cardiac arrest, and any externally obtained carboxyhemoglobin levels. Hospital discharge disposition determined acute mortality occurring during the visit. To determine 1-year mortality, we censored those who died in-hospital, then examined which patients had a health encounter greater than 1 year from the CO poisoning discharge date. The patients who did not have a visit greater than 1 year from initial CO poisoning were then compared with the U.S. Social Security Death Index to determine if death occurred in that year.
Utility of Clinical Assessments in CO Poisoning
To assess the utility of standard clinical measures to assess CO poisoning, we created variables that combined factors used to diagnose or risk stratify CO-poisoned patients (5, 20) (Fig. 1) . Cardiac manifestations in moderate and severe CO poisoning are associated with long-term mortality (5). We created "cardiac complication" variable from any the following events: cardiac event mentioned in the clinical chart (cardiac arrest, shock, arrhythmia, or myocardial infarction), an elevated serum troponin greater than 0.10 ng/mL, or shock requiring vasopressors or inotropes. We created a "high-risk" variable for any with risks associated with high short-term mortality: greater than 25% carboxyhemoglobin, loss of consciousness (syncope), pH less than 7.20, fire exposure or any cardiac complication, including cardiac arrest (20) .
Statistical Analysis
Baseline characteristics and clinical outcomes were expressed as median and interquartile ranges (continuous variables) or as percentages (categorical variables). Univariate analysis of variables between groups with and without HBo 2 or inpatient hospital admission was compared using Student t tests or Wilcoxon ranksum tests, as appropriate, for continuous variables, and using chi-square tests for categorical variables. We used receiver operating characteristics (ROC) curve to assess the ability of clinical variables to predict the outcome of interest as well to determine the optimal cut point of carboxyhemoglobin with best predictive ability for study outcomes.
We applied propensity score, nearest neighbor matching, with a caliper width of 0.05, to analyze the effect of HBo 2 on inpatient and 1-year mortality, compared with matched CO poisoning patients who did not receive HBo 2 (21) . Variables that best predicted HBo 2 use were selected using logistic regression to enter into the propensity score analysis (21) . For inpatient mortality, no subject was excluded. For 1-year mortality, 12 initial poisoning survivors were lost to follow-up. The total average treatment effect after matching was reported with acceptable (< 0.1) standardized difference of propensity score predictors. A two-sided p value of less than 0.05 was considered statistically significant. All statistical analyses were performed with Stata 14.2 (StataCorp LP, College Station, TX).
RESULTS
Patient Characteristics
One-thousand ninety-nine (1,099) unique patient encounters were identified with CO poisoning during the study period (January 2000 to April 2014) ( Table 1 ). The median age was 44 years (range, 18-95 yr). Eighty percent of the identified patients had an abnormal carboxyhemoglobin level (≥ 3%) recorded.
Critical Care Medicine
The most common symptom at presentation was headache (55%), and the most frequent complications were altered mentation and syncope (each 25%). Eleven percent of patients had a cardiac complication, including nine with atrial fibrillation (which may have been chronic). Thirty-nine percent of patients had at least one high-risk feature.
We found that 27% of patients were admitted for inpatient management, including 8.3% who required ICU admission. Notably, 18% of the study population was transferred from another hospital. Transfer patients were more likely to fit "highrisk" criteria (44.9%) (Supplemental Table 1 , Supplemental Digital Content 1, http://links.lww.com/CCM/D445).
HBo 2 Determination
We found 26% of patients received HBo 2 . The variable that best predicted HBo 2 utilization, as demonstrated by the largest ROC area under the curve (AUC), was a carboxyhemoglobin level greater than or equal to 19.0%, present in 39% of patients. Other features associated with HBo 2 use were older age, male sex, and an elevated troponin greater than 0.10 ng/mL ( Table 2; and Supplemental Table 2 , Supplemental Digital Content 2, http://links.lww.com/CCM/D446). Of those receiving HBo 2 , 91% had at least one high-risk feature (cardiac complication, carboxyhemoglobin > 25%, pH < 7.20, fire exposure or syncope) versus 21% in those not receiving HBo 2 . Among patients who had cardiac arrest, 30% had HBo 2 versus 26% in other patients (p = 0.7).
Over 75% of the patients who were transferred from an outside hospital received HBo 2 . More patients receiving HBo 2 were admitted (53% vs 18% of no HBo 2 ). More patients receiving HBo 2 were admitted to the ICU (14% vs 6%) ( Table 2) .
Acute Mortality in CO Poisoning
We found 1.3% of patients died during the initial CO poisoning visit. Factors associated with in-hospital death were older age, fire exposure, loss of consciousness or syncope, and respiratory distress (mechanical ventilation and/or failure to protect airway due to coma), cardiac complications, and elevated carboxyhemoglobin levels ( Table 3; and Supplemental Table 3 , Supplemental Digital Content 3, http://links. lww.com/CCM/D447).
We determined that a carboxyhemoglobin level greater than or equal to 29.0% best predicted in-hospital death using the AUC of the ROC. Ten patients (0.9%) had a cardiac arrest. Acute mortality was 70% among patients with cardiac arrest versus 0.7% in others (p < 0.001).
1-Year Mortality After CO Poisoning
Among 1,073 survivors of initial CO poisoning, 2.9% died by 1 year and 4.4% died by 2 years after initial poisoning. Factors associated with 1-year mortality were older age, male sex, respiratory distress, renal dysfunction, and elevated serum troponin levels greater than 0.10 ng/dL (Table 3; and Supplemental  Table 4 , Supplemental Digital Content 4, http://links.lww.com/ CCM/D448). In patients with initial cardiac arrest that survived (n = 3), mortality was 33.3% versus 2.9% in others (p = 0.087).
HBo 2 and Mortality
Variables identified as most significantly associated with HBo 2 on univariate analysis (cardiac complication, respiratory distress, syncope, altered mental status and elevated carboxyhemoglobin blood levels) were used to calculate a propensity score (AUC for predicting HBo 2 = 0.93). In propensity score adjustment analysis, HBo 2 treatment was associated with an average 2.1% absolute risk reduction ([3.7-0.9%]; p = 0.001) in inpatient mortality (corresponding relative risk [RR], 0.13). After propensity matching, the standardized difference between treated and not treated groups were in range of 0.00-0.04. Mean standardized carboxyhemoglobin level difference between treated and propensity score-matched untreated patients was 0.4%. Using this same propensity score analysis, HBo 2 was associated with a 2.1% absolute risk reduction ([3.8-0.4%]; p = 0.013) in 1-year mortality (corresponding RR, 0.30). The standardized difference of predictors between treated and untreated was 0.00-0.06. In a sensitivity analysis, instead using gender and cardiac complication to calculate the propensity score, HBo 2 treatment was associated with 2.5% absolute risk reduction (p = 0.005) in inpatient mortality (corresponding RR, 0.19).
Effect of Fire Exposure and Higher Carboxyhemoglobin Levels
Although we did not have data available for smoke inhalation or concomitant cyanide poisoning, known markers for worse outcome (2), fire exposure as a source of CO poisoning was recorded. We found that in a subgroup analysis of those patients with fire exposure, HBo 2 treatment was associated with lower acute mortality (p = 0.026) but not 1-year mortality (p = 0.6).
We identified patients using International Classification of Diseases, 9th revision (ICD-9), codes for CO poisoning. This included more mildly poisoned patients with carboxyhemoglobin levels less than 10%. Thus, we analyzed the subgroup of more severely poisoned patients with carboxyhemoglobin levels greater than 10% (a high carboxyhemoglobin level even for smokers). In the subgroup of patients with carboxyhemoglobin greater than 10%, HBo 2 treatment was associated with lower acute mortality (p = 0.001) but not 1-year mortality (p = 0.2).
DISCUSSION Population
The number of patients admitted to the hospital was high (27%) compared with prior estimates as low as 11% (22) . Almost 10% of patients required admission to the ICU. Nearly 20% of patients treated for CO poisoning required hospital transfer, highlighting the logistical barriers to expedient management of CO poisoning (1, 2).
HBo 2 Use
HBo 2 clinical indications have not been extensively studied in the past (1, 2, 13, 23) . Presence of any high-risk features (carboxyhemoglobin level > 25.0%, severe acidosis, syncope, fire exposure, and cardiac complication) predicted HBo 2 use well (OR, 27.76 [17.35-44 .30]; p < 0.001) ( Table 2 ). Although it is recommended those with a CO exposure lasting greater than 24 hours receive HBo 2 , we could not test this hypothesis due to the limitations of our clinical data and chart review.
Acute Mortality
An acute mortality of 1.3% agrees with much of the reported literature on CO poisoning (1, 2, 24) . Previous authors have shown that fire as a source of CO, loss of consciousness, carboxyhemoglobin level, arterial pH, and presence of endotracheal intubation during hyperbaric treatment are significantly associated with mortality (1, 2, 24). We similarly found that fire exposure, syncope, very high carboxyhemoglobin levels (≥ 29.0%), low pH (< 7.20), and respiratory distress were significantly associated with inpatient mortality. Similar to a previous study, patients with cardiac arrest associated with CO poisoning had high mortality (70%) (25).
1-Year Mortality
Larger population studies have shown an increased mortality both in the subacute and chronic time period after CO poisoning (7) . Cardiac injury at initial poisoning has been reported to be associated with double the long-term mortality of patients who do not have cardiac dysfunction (5) . There is increased risk of death overall in CO survivors, largely from alcoholism, accidental injury, and intentional self-harm, suggesting underlying neurologic or psychiatric complications (6) . There is known to be a higher risk of acute and long-term death in intentional versus accidental poisonings (6) . In our study, we were not able to examine the nature of the CO poisoning event in regard to intent. We found that the strongest factors associated with 1-year mortality were older age, cardiac complication, respiratory distress, and a high serum creatinine. There was no association between carboxyhemoglobin level and 1-year mortality. This suggests that the more important factors in 1-year mortality are related to underlying chronic health status and older age.
HBo 2 Is Associated With Improved Survival
There is only one HBo 2 randomized control trial meeting Consolidated Standards Of Reporting Trials criteria (26) which showed that there was a reduction in long-term neurocognitive deficits (8) . A Cochrane Review meta-analysis performed on six clinical trials showed no net benefit from HBo 2 on neurocognitive outcome (13) . Critical care propensity score analyses are generally consistent with the findings of randomized clinical trials in this difficult to study population (27) . The factors used to build the propensity score are in agreement with the recommendations of hyperbaric medicine experts for patients who should receive HBo 2 (2). Higher carboxyhemoglobin levels, syncope (or coma causing respiratory distress), and cardiac complications are associated with increased death in CO poisoning (20) . We show that HBo 2 is associated with a benefit for both inpatient (odds ratio [OR], 0.13 death) and 1-year mortality (OR, 0.30 1 yr death) using propensity score analysis. Although our study is a retrospective analysis, these data suggest a potential mortality benefit to receiving HBo 2 . Our findings should be replicated in other cohorts of patients before wide application to clinical use.
In subgroup analysis of patients with fire exposure and with carboxyhemoglobin levels greater than 10%-presumably more severely poisoned patients-we found that HBo 2 was significantly associated with reduced inpatient acute mortality in each. Critically ill CO-poisoned patients may have an acute survival benefit to HBo 2 despite treatment risks and logistical difficulties 
LIMITATIONS
Despite the strengths of our analysis and the validity of our data, the study has several limitations. There are inherent limitations in an observational clinical databank-based study. The missing data (not all patients had laboratory studies performed), data accuracy, including ICD-9 codes, are potential sources for error (28) . Although we attempted to identify those with significant smoke inhalation and fire exposure through chart review, we could not delineate concomitant burn exposures and/or cyanide exposure. Propensity score analysis cannot exclude confounding as well as a randomized control trial. There is a potential that the sickest patients never could receive HBo 2 and thus, confounded the association of HBo 2 with improved survival we detected with selection bias. We found higher rates of inpatient admission in our study (27%) than some prior estimates (11%) (22) . This may have been biased because of the presence of several regional referral centers in the database. These factors could limit the generalizability of our findings.
CONCLUSIONS
In this study, we assess a database of over 1,000 CO-poisoned adults. Because there is a low overall acute mortality rate, a randomized control trial would be difficult to power to test for mortality benefit. A study such as ours may be the only way to associate a mortality benefit to HBo 2 . We found that HBo 2 treatment is associated with improved survival in both the acute and long-term setting. Our results in this retrospective cohort of CO poisoning patients should warrant further investigation into the efficacy HBo 2 in CO poisoning. 
